GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Integra Lifesciences Holdings Corp (STU:IL3) » Definitions » Change In Receivables

Integra Lifesciences Holdings (STU:IL3) Change In Receivables : €5 Mil (TTM As of Dec. 2024)


View and export this data going back to . Start your Free Trial

What is Integra Lifesciences Holdings Change In Receivables?

Integra Lifesciences Holdings's change in receivables for the quarter that ended in Dec. 2024 was €-30 Mil. It means Integra Lifesciences Holdings's Accounts Receivable increased by €30 Mil from Sep. 2024 to Dec. 2024 .

Integra Lifesciences Holdings's change in receivables for the fiscal year that ended in Dec. 2024 was €7 Mil. It means Integra Lifesciences Holdings's Accounts Receivable declined by €7 Mil from Dec. 2023 to Dec. 2024 .

Integra Lifesciences Holdings's Accounts Receivable for the quarter that ended in Dec. 2024 was €260 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Integra Lifesciences Holdings's Days Sales Outstanding for the three months ended in Dec. 2024 was 56.15.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Integra Lifesciences Holdings's liquidation value for the three months ended in Dec. 2024 was €-1,719 Mil.


Integra Lifesciences Holdings Change In Receivables Historical Data

The historical data trend for Integra Lifesciences Holdings's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integra Lifesciences Holdings Change In Receivables Chart

Integra Lifesciences Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.83 6.43 -32.01 4.21 7.07

Integra Lifesciences Holdings Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.42 15.48 -6.24 25.90 -30.05

Integra Lifesciences Holdings Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Integra Lifesciences Holdings  (STU:IL3) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Integra Lifesciences Holdings's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=260.113/422.727*91
=56.15

2. In Ben Graham's calculation of liquidation value, Integra Lifesciences Holdings's accounts receivable are only considered to be worth 75% of book value:

Integra Lifesciences Holdings's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=261.256-2379.998+0.75 * 260.113+0.5 * 409.781
=-1,719

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Integra Lifesciences Holdings Change In Receivables Related Terms

Thank you for viewing the detailed overview of Integra Lifesciences Holdings's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Integra Lifesciences Holdings Business Description

Traded in Other Exchanges
Address
1100 Campus Road, Princeton, NJ, USA, 08540
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.

Integra Lifesciences Holdings Headlines

No Headlines